Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations - PubMed (original) (raw)

. 2011 Sep 10;29(26):3574-9.

doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8.

Affiliations

• PMID: 21825258
• DOI: 10.1200/JCO.2011.35.9638

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations

Antonio Marchetti et al. J Clin Oncol. 2011.

Abstract

Purpose: To investigate the prevalence, distribution, and prognostic role of BRAF mutations in a large cohort of white patients with non-small-cell lung cancer (NSCLC).

Patients and methods: A retrospective series of 1,046 NSCLCs-comprising 739 adenocarcinomas (ADCs) and 307 squamous cell carcinomas (SCCs)-was investigated for BRAF mutations. High-resolution melting analysis followed by sequencing and strip hybridization assay were used. All patients were also analyzed for KRAS and EGFR mutations.

Results: BRAF mutations were present in 36 ADCs (4.9%) and one SCC (0.3%; P = .001). Twenty-one of the mutations (56.8%) were V600E, and 16 (43.2%) were non-V600E. V600E mutations were significantly more prevalent in females (16 of 187 patients; 8.6%) than in males (five of 552 patients; 0.9%), as indicated by multivariate logistic regression analysis (hazard ratio [HR], 11.29; P < .001). V600E-mutated tumors showed an aggressive histotype characterized by micropapillary features in 80% of patients and were significantly associated with shorter disease-free and overall survival rates on both univariate (HR, 2.67; P < .001 and HR, 2.97; P < .001, respectively) and multivariate analyses (HR, 2.19; P = .011 and HR, 2.18; P = .014, respectively). All non-V600E mutations were found in smokers (P = .015) and were associated with neither clinicopathologic parameters nor prognosis. BRAF and EGFR were concomitantly mutated in two tumors.

Conclusion: We report for the first time to our knowledge that V600E and non-V600E BRAF mutations affect different patients with NSCLC. V600E mutations are significantly associated with female sex and represent a negative prognostic factor. In addition, we identified a number of other clinicopathologic parameters potentially useful for the selection of patients carrying BRAF mutations.

PubMed Disclaimer

Similar articles

• Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
  Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ. Tissot C, et al. Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15. Lung Cancer. 2016. PMID: 26711930
• Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
  Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R. Kinno T, et al. Ann Oncol. 2014 Jan;25(1):138-42. doi: 10.1093/annonc/mdt495. Epub 2013 Dec 1. Ann Oncol. 2014. PMID: 24297085
• Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
  Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY. Lee SY, et al. J Thorac Oncol. 2010 Nov;5(11):1734-40. doi: 10.1097/JTO.0b013e3181f0beca. J Thorac Oncol. 2010. PMID: 20881644
• BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
  Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D. Leonetti A, et al. Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Cancer Treat Rev. 2018. PMID: 29729495 Review.
• A BRAF new world.
  Frisone D, Friedlaender A, Malapelle U, Banna G, Addeo A. Frisone D, et al. Crit Rev Oncol Hematol. 2020 Aug;152:103008. doi: 10.1016/j.critrevonc.2020.103008. Epub 2020 May 26. Crit Rev Oncol Hematol. 2020. PMID: 32485528 Review.

Cited by

• Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan.
  Ikeda S, Hasegawa K, Kachi K, Yanagisawa A, Kawakami S, Hamasaki S, Watanabe S, Yoshikawa A, Takahama T, Nakagawa K. Ikeda S, et al. Cancer Med. 2024 Nov;13(21):e70375. doi: 10.1002/cam4.70375. Cancer Med. 2024. PMID: 39494523 Free PMC article.
• Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
  Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Cardarella S, et al. Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833300 Free PMC article.
• Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives.
  Takeda H, Sunakawa Y. Takeda H, et al. Front Oncol. 2021 Mar 25;11:602194. doi: 10.3389/fonc.2021.602194. eCollection 2021. Front Oncol. 2021. PMID: 33842313 Free PMC article. Review.
• Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.
  Desai A, Menon SP, Dy GK. Desai A, et al. Cancer Biol Med. 2016 Mar;13(1):77-86. doi: 10.28092/j.issn.2095-3941.2016.0008. Cancer Biol Med. 2016. PMID: 27144064 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal